Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $1137

Benzinga · 10/16 14:42
Truist Securities analyst Srikripa Devarakonda maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $1200 to $1137.